Entering into collaborations and licensing arrangements is a component of our business strategy. We seek to create value by advancing our development programs through preclinical studies and early-stage clinical trials and subsequently collaborating with major pharmaceutical companies for late-stage development and commercialization.

We have licensed the use of our MSCRAMM^® protein platform to Pfizer for the development of human staphylococcal vaccines under an exclusive worldwide license and development agreement. Pfizer has recently completed a Phase 1 trial with a multi-component S. aureus vaccine in healthy subjects and in August 2011, they initiated a randomized, double-blind Phase 1/ 2 clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 4-antigen Staphylococcus aureus (S. aureus) vaccine (SA4Ag) in 1,068 healthy adults. The vaccine contains an antigen originating from our proprietary MSCRAMM^® protein platform. Pfizer is responsible for all clinical development, manufacturing and marketing of the vaccine. We are also eligible to receive future regulatory milestones and royalties on any future net sales.




Please contact bd@inhibitex.com for additional information concerning partnering with Inhibitex.